secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001437749-25-031637
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx subsidiary HOPE Therapeutics acquires minority interest in Cohen & Associates; Dr. Cohen named Medical Director
--------------------------------------------------------------------------------

- HOPE Therapeutics acquired strategic minority interest in Rebecca S. Cohen, MD, LLC (Cohen & Associates) of Sarasota, FL, effective Oct 17, 2025.
- Dr. Rebecca Cohen appointed Medical Director of HOPE Therapeutics, overseeing medical standards in Florida locations.
- Cohen & Associates offers TMS, ketamine, and medication management for depression, PTSD, and CNS disorders.
- Immediate expansion planned in Western Florida and Palm Beach.
- Acquisition expected to be accretive to HOPE Therapeutics revenue and EBITDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925031637/0001437749-25-031637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925031637/nrxp20251023_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-031637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer